Costs associated with persistent allergic rhinitis are reduced by levocetirizine

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 60, Issue 6, 2005, Pages 788-794

  Bousquet, J ^a   Demarteau, N ^b   Mullol, J ^c   Van Den Akker Van Marle, M E ^d   Van Ganse, E ^e   Bachert, C ^f  

^a HÔPITAL ARNAUD DE VILLENEUVE   (France)

^b UCB PHARMA   (Belgium)

^c HOSPITAL CLÍNIC   (Spain)

^d TNO   (Netherlands)

^e UNIVERSITÉ LYON 1   (France)

^f GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Antihistamine; Cost; Levocetirizine; Persistent allergic rhinitis; Time lost

Indexed keywords

ANTIHISTAMINIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CROMOGLYCATE DISODIUM; LEVOCETIRIZINE; PLACEBO; PREDNISOLONE;

ABSENTEEISM; ALLERGIC RHINITIS; ARTICLE; ASTHMA; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DAILY LIFE ACTIVITY; DRUG COST; EMPLOYER; FRANCE; HEALTH CARE COST; HOSPITAL COST; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OTITIS; PHYSICIAN; PRIORITY JOURNAL; QUALITY OF LIFE; SINUSITIS; SOCIAL SECURITY; SOCIETY; UPPER RESPIRATORY TRACT INFECTION; WORKING TIME;

CETIRIZINE; COST OF ILLNESS; COSTS AND COST ANALYSIS; EUROPE; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; PIPERAZINES; QUALITY OF LIFE; RHINITIS, ALLERGIC, PERENNIAL;

EID: 20044377632     PISSN: 01054538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1398-9995.2005.00820.x     Document Type: Article

References (29)

1. Bousquet J. Van Cauwenberge P, Khaltaev N, Aria Workshop Group, World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001;108: S147-334.
2. Demoly P, Allaert FA, Lecasble M, Bousquet J, PRAGMA. Validation of the classification of ARIA (allergic rhinitis and its impact on asthma). Allergy 2003;58:672-675.
3. Bauchau V, Durham SR. Prevalence and rate of diagnosis of allergic rhinitis in Europe. Eur Respir J 2004;24:758-764.
4. Reed SD, Lee TA, McCrory DC. The economic burden of allergic rhinitis: a critical evaluation of the literature. Pharmacoeconomics 2004;22:345-361.
5. Dessi P, Allaert FA, Urbinelli R, Verriere JL. Medico-economic aspects of the management of perennial allergic rhinitis in general medicine. Allerg Immunol (Paris) 1998;30:277-283.
6. Levebvre S, Daures J-P, Sartor F, Walckiers D, El Hasnaoui A. Estimination of French epilepsy prevalence rate from drug sales data. Pharmacoepidemiology and drug safety 2001;10:S57-S58.
7. De Zelicourt M, Buteau L, Fagnani F, Jallon P. The contributing factors to medical cost of epilepsy: an estimation based on a French prospective cohort study of patients with newly diagnosed epileptic seizures (the CAROLE study). Active Coordination of the Longitudinal Observational Network in Epilepsy. Seizure 2000;9:88-95.
8. Selke B, Durand I, Marissal JP, Chevalier D, Lebrun T. Cost of colorectal cancer in France in 1999. Gastroenterol Clin Biol 2003;27:22-27.
9. Marshall JB. Socio-economic costs of allergic diseases. In: European Allergy White Paper, UCB Institute of Allergy, 1997;98-110.
10. McMenamin P. Costs of hay fever in the United States in 1990. Ann Allergy 1994;73:35-39.
11. Malone DC, Lawson KA, Smith DH, Arrighi HM, Battista C. A cost of illness study of allergic rhinitis in the United States. J Allergy Clin Immunol 1997;99:22-27.
12. Storms W, Meltzer EO, Nathan RA. The economic impact of allergic rhinitis. J Allergy Clin Immunol 1997;99: S820-824.
13. Sculpher M. The role and estimation of productivity costs in economic evaluation. In: Drummond M, McGuire A, editors. Economic evaluation in health care: merging theory with practice. New York: Oxford University Press, 2001:94-112.
14. Wang PS, Beck A, Berglund P, Leutzinger JA, Pronk N, Richling D et al. Chronic medical conditions and work performance in the health and work performance questionnaire calibration surveys. J Occup Environ Med 2003;45:1303-1311.
15. Reilly MC, Tanner A, Meltzer EO. Work, classroom and activity impairment instruments. Validation studies in allergic rhinitis. Clinical Drug Investigation 1996;11:278-288.
16. Cockburn IM, Bailit HL, Berndt ER, Finkelstein SN. Loss of work productivity due to illness and medical treatment. J Occup Environ Med 1999;41:948-953.
17. Weiss KB. Cost implications of upper respiratory allergic diseases. J Allergy Clin Immunol 1998;101:S383-385.
18. Spector SL. Overview of comorbid associations of allergic rhinitis. J Allergy Clin Immunol 1997;99:S773-780.
19. Ray NF, Baraniuk JN, Thamer M, Rinehart CS, Gergen PJ, Kaliner M. Direct expenditures for the treatment of allergic rhinoconjunctivitis in 1996, including the contributions of related airway illnesses. J Allergy Clin Immunol 1999;103:401-407.
20. Schramm B, Ehlken B, Smala A, Quednau K, Berger K, Nowak D. Cost of illness of atopic asthma and seasonal allergic rhinitis in Germany: 1-yr retrospective study. Eur Respir J 2003;21:116-122.
21. Yawn BP, Yunginger JW, Wollan PC, Reed CE, Silverstein MD, Harris AG. Allergic rhinitis in Rochester, Minnesota residents with asthma: frequency and impact on health care charges. J Allergy Clin Immunol 1999;103:54-59.
22. Didier A, Chanal I, Klossek JM, Mathieu J. La rhinite allergique: le point de vue du patient. Rev Fr Allergol 1999;39:171-185.
23. Bachert C, Bousquet J, Canonica GW, Durham SR, Klimek L, Mullol J et al. Levocetirizine improves quality of life and reduces costs in long-term management of persistent allergic rhinitis. J Allergy Clin Immunol 2004;114:838-844.
24. Drummond MF, O'Brien BJ, Stoddart GL, Torrance GW. Method for the Economic Evaluation of Health Care Programmes. Oxford: Oxford University Press, 1997.
25. Liljas B. How to calculate indirect costs in economic evaluations. Pharmacoeconomics 1998;13:1-7.
26. Koopmanschap MA, Rutten FF, van Ineveld BM, van Roijen L. The friction cost method for measuring indirect costs of disease. J Health Econ 1995;14:171-189.
27. Barber JA, Thompson SG. Analysis of cost data in randomized trials: an application of the non-parametric bootstrap. Stat Med 2000;19:3219-3236.
28. Heyse J, Cook J, Carides G. Statistical considerations in analysing health care resource utilization and cost data. In: Drummond M, McGuire A. editors. Economic evaluation in health care: merging theory with practice. New York: Oxford University Press. 2001:215-235.
29. Law AW, Reed SD, Sundy JS, Schulman KA. Direct costs of allergic rhinitis in the United States: estimates from the 1996 Medical Expenditure Panel Survey. J Allergy Clin Immunol 2003;111:296-300.